RA Capital-backed non-viral gene therapy startup Summation Bio to shut down
As a string of new gene therapy startups aims to create treatments without the go-to shuttling method of an AAV virus, and as multiple gene editing biotechs look to do the same, one such startup is coming to a close.
Summation Bio, backed by at least $24 million in Series A funds, is “terminating operations” next month, per an employee’s LinkedIn profile update. (According to their LinkedIn profile, an employee said the company raised $60 million in the round.) Another employee took to the networking site last week to say the circumstances were “insurmountable,” noting that “despite all-out effort and error-free execution, the science, this time, was elusive.”
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.